For decades, anticancer targeted therapies have been designed to inhibit kinases or other
enzyme classes and have profoundly benefited many patients. However, novel approaches …

Although the majority of patients with acute myeloid leukemia (AML) treated with intensive
chemotherapy achieve a complete remission (CR), many are destined to relapse if treated …

Acute myeloid leukaemia (AML) is the commonest indication for allogeneic stem cell
transplantation (allo‐SCT) worldwide. The accumulated experience of allografting in AML …

Abstract Programmed cell death-1 (PD-1)/programmed death ligand-1 blockade may
potentially augment graft-vs-tumor effects following allogeneic hematopoietic cell …

Allogeneic hematopoietic stem cell transplantation (HSCT) for high-risk acute myeloid
leukemia (AML) represents the only curative option. Progress has been made in the last two …

Immune surveillance of incipient tumor cells is important for defense against cancer
development. However, active immune evasion is a cancer hallmark. 1 In acute myeloid …

Juvenile myelomonocytic leukemia (JMML) is a rare pediatric leukemia characterized by
mutations in five canonical RAS pathway genes. The diagnosis is made by typical clinical …

With advances in allogeneic hematopoietic stem cell transplant (allo-HCT), disease relapse
has replaced transplant-related mortality as the primary cause of treatment failure for …

Acute myeloid leukemia (AML) is a cancer that originates from the bone marrow (BM). Under
physiological conditions, the bone marrow supports the homeostasis of immune cells and …

Acute Myeloid Leukemia (AML) is the prototype of cancer genomics as it was the first
published cancer genome. Large-scale next generation/massively parallel sequencing …